Christopher R. Andersen

Christopher R. Andersen

Auto-generated profile, based on publicly available information

Christopher R. Andersen

Immunovirology and Pathogenesis Program, Kirby Institute, University of New South Wales, Sydney, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2018 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
CAChristopher R. Andersen
Christopher R. Andersen
EFEmily Fitzgerald
Emily Fitzgerald
ADAnthony Delaney
Anthony Delaney
SFSimon Finfer
Simon Finfer

1 December 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
CAChristopher R Andersen
Christopher R Andersen
JPJustin Presseau
Justin Presseau
VSVictoria Saigle
Victoria Saigle
NENima Etminan
Nima Etminan
MVMervyn D I Vergouwen
Mervyn D I Vergouwen
SEShane W English
Shane W English

1 January 2011
Verified
Journal Article
Closed access
CMC. Mee Ling Munier
C. Mee Ling Munier
CAChristopher R. Andersen
Christopher R. Andersen
AKAnthony D. Kelleher
Anthony D. Kelleher

1 August 2020 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
LQLiam Quinn
Liam Quinn
DTDavid H. Tian
David H. Tian
EFEmily Fitzgerald
Emily Fitzgerald
OFOliver Flower
Oliver Flower
CAChris Andersen
Chris Andersen
ADAnthony Delaney
Anthony Delaney

15 May 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PHPriyanka Hastak
Priyanka Hastak
DCDeborah Cromer
Deborah Cromer
JMJames Malycha
James Malycha
CAChristopher R. Andersen
Christopher R. Andersen
EREamon Raith
Eamon Raith
SSSarah C. Sasson
Sarah C. Sasson
Lymphopenia is a common feature of acute COVID-19 and is associated with increased disease severity and 30-day mortality. Here we aim to define the demographic and clinical characteristics that correlate with lymphopenia in COVID-19 and determine if lymphopenia is an independent predictor of poor clinical outcome. We analysed the ENTER-COVID (Epidemiology of hospitalized in-patient admissions following planned introduction of Epidemic SARS-CoV-2 to highly vaccinated COVID-19 naïve population) dataset of adults (N = 811) admitted for COVID-19 treatment in South Australia in a retrospective registry study, categorizing them as (a) lymphopenic (lymphocyte count < 1 × 109/L) or (b) non-lymphopenic at hospital admission. Comorbidities and laboratory parameters were compared between groups. Multiple regression analysis was performed using a linear or logistic model. Intensive care unit (ICU) patients and non-survivors exhibited lower median lymphocyte counts than non-ICU patients and survivors respectively. Univariate analysis revealed that low lymphocyte counts associated with hypertension and correlated with haemoglobin, platelet count and negatively correlated with urea, creatinine, bilirubin, and aspartate aminotransferase (AST). Multivariate analysis identified age, male, haemoglobin, platelet count, diabetes, creatinine, bilirubin, alanine transaminase, c-reactive protein (CRP) and lactate dehydrogenase (LDH) as independent predictors of poor clinical outcome in COVID-19, while lymphopenia did not emerge as a significant predictor.

25 September 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
PHPriyanka Hastak
Priyanka Hastak
CAChristopher R. Andersen
Christopher R. Andersen
PCPhoebe Crammond
Phoebe Crammond
ZZZong-Hong Zhang
Zong-Hong Zhang
CPChansavath Phetsouphanh
Chansavath Phetsouphanh
SSSarah C. Sasson
Sarah C. Sasson
Acute lung injury (ALI) is characterised by hypoxia and inflammation that derives from diverse aetiologies. Delineating the molecular pathogeneses may identify treatable subgroups and inform clinical trials. Using a multi-omics approach, we analysed trauma-associated ALI (n = 9), COVID-19 ALI (n = 11), ICU controls (n = 13) using scRNA-seq, serum cytokine profiling, and bronchoalveolar lavage (BAL) microbiome analysis. We identified a population of activated CD4+ T cells expressing Toll-like receptor 4 (TLR4) and downstream NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome complex, predominantly in trauma-associated ALI (23% of CD45+ Cells) compared to COVID-19 ALI (14%) and ICU controls (15%). Serum IL-1RA and IL-6 were upregulated in trauma ALI, along with TLR4-binding ligand hyaluronan. TLR4 expression on CD4+ T cells was confirmed by spectral cytometry. Lung microbiome analysis revealed distinct diversity in trauma-associated ALI compared to COVID-19 ALI. These findings highlight TLR4-mediated inflammation in trauma-associated ALI and suggest potential precision medicine approaches for ALI management.